Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Semin Nephrol. 2018 Mar;38(2):175–182. doi: 10.1016/j.semnephrol.2018.01.006

Table 2.

Paraneoplastic manifestations are present in up to 10–40% of patients with renal cell carcinoma

ENDOCRINE NON-ENDOCRINE
Hypertension Kidney failure
Polycythemia Anemia
Hepatic dysfunction (not due to metastasis) Coagulopathy
Hypercalcemia Neuropathy and myopathy
Cushing’s syndrome Vasculopathy
Glucose metabolism alterations Amyloidosis
Galactorrhea